Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

DNA, plasmid and preparation capable of directionally clearing HBV (Hepatitis B virus) ccc in hepatocyte

A preparation and technology of hepatitis B virus, applied in the field of biological macromolecular pharmaceutical preparations, can solve the problems of lack of safe and effective preparations for in vivo application, and achieve the effects of reducing antigen expression level, high transfection efficiency and reducing replication

Active Publication Date: 2017-05-31
SHANGHAI JIAO TONG UNIV
View PDF3 Cites 35 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] However, most of the CRISPR / Cas systems in current research are transfected by viral vectors or hydrodynamic injection, and there is a lack of a safe and effective preparation for in vivo application.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • DNA, plasmid and preparation capable of directionally clearing HBV (Hepatitis B virus) ccc in hepatocyte
  • DNA, plasmid and preparation capable of directionally clearing HBV (Hepatitis B virus) ccc in hepatocyte
  • DNA, plasmid and preparation capable of directionally clearing HBV (Hepatitis B virus) ccc in hepatocyte

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0078] Example 1 Design, synthesis and eukaryotic expression vector construction of sgRNA sequence

[0079] We chose to target different subtypes of HBV genomes: adw (Genebank ID: AF100309.1), adw2 (Genebank ID: X02763), adr (Genebank ID: AF411411), ayw (Genebank ID: V01460.1) as CRISPR / Cas The targeting sequence of the system is used as the targeting sequence of the CRISPR / Cas system, and multiple sgRNAs targeting the conserved regions of the viral genome were designed according to the sgRNA design principles. Compare the obtained sgRNA with the human genome sequence, exclude the sgRNA with high homology, and finally find five new sgRNA targets and target sequences (as shown in Table 1 & as shown in Table 1). figure 1 shown).

[0080] Table 1

[0081]

[0082]According to the selected target sequence, we first synthesized the corresponding sgRNA insert sequence: GN 19, and the GN 19 sequence was annealed and cloned into the linearized pAdeno-U6-sgRNA-CMV-3Flag-hCas9 vect...

Embodiment 2

[0090] Five kinds of CRISPR / Cas9 expression plasmids (sg1, sg2, sg3, sg4, sg5) constructed in Example 1 were co-transfected into SMMC-7721 cells with the pHBV1.3 plasmid, and the virus surface antigen, e antigen, Changes in the cccDNA of hepatitis B virus, and based on this, the effects of five CRISPR / Cas9 systems on inhibiting HBV replication were evaluated.

[0091] (1) Cell transfection After mixing pHBV 1.3 and CRISPR / Cas9 plasmids, SMMC-7721 cells were transfected with lipofectamine 2000, and pHBV 1.3 was mixed with pGl3 plasmids as a control group. Cultured for 48h after transfection, culture medium and cells were collected for subsequent assay experiments.

[0092] (2) Determination of hepatitis B surface antigen and e antigen The above cells were centrifuged, and the cell supernatant was collected. The hepatitis B surface antigen and e antigen in the supernatant were measured with the hepatitis B virus surface antigen diagnostic kit and the hepatitis B virus e antigen...

Embodiment 3

[0100] The preparation of embodiment 3 cationic lipid nucleic acid drug preparation

[0101] Cationic lipids are prepared using DOTAP as an example, and nucleic acid drugs are prepared using CRISPR / Cas9 as an example (sg1, sg2, sg3, sg4, sg5).

[0102] The pH-responsive lipid used in this example is lipid CA, which is a prior art. The structural formula of the lipid CA is as shown in formula II, specifically:

[0103]

[0104] Those skilled in the art can use the method reported in the document "Controlling HBV Replication in Vivo by Intravenous Administration of Triggered PEGylated siRNA-Nanoparticles" to prepare and obtain lipid CA.

[0105] Such as Figure 4 As shown, the lipid CA reacts with PEG whose terminal group is an aldehyde group to obtain PEGylated lipid CA. The structural formula of the PEGylated lipid CA is shown in formula III, specifically:

[0106]

[0107] (1) Preparation of blank liposomes: Take a certain amount of DOTAP / DOPE / CA lipid stock solutio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
Login to View More

Abstract

The invention belongs to the technical field of bio-macromolecular pharmaceutical preparations, and specifically relates to a DNA, a plasmid and a preparation capable of directionally clearing HBV (Hepatitis B virus) ccc in hepatocyte. According to the invention, five brand-new CRISPR / Cas systems are discovered through wide and in-depth studies, and can effectively clear HBV ccc DNA in cells, inhibit reproduction of HBVs, and reduce expression of proteins related to the HBVs. A pH-sensitive and PEG-modified cationic lipid carrier is further prepared, and has the advantages of good stability and high transfection efficiency; and internal instability of multiple cationic lipid carriers is overcome. The CRISPR / Cas systems are combined with the pH-sensitive and PEG-modified cationic lipid carrier to prepare a CRISPR / Cas9 cationic lipid carrier preparation which can effectively inhibit virus reproduction in a murine model suffering from acute HBV infection and reduce antigen expression level.

Description

technical field [0001] The invention belongs to the field of biomacromolecule pharmaceutical preparations, and in particular relates to a class of DNA, plasmids and preparations for directional elimination of HBV ccc in liver cells. Background technique [0002] Hepatitis B is an infectious disease caused by hepatitis B virus (Hepatitis B virus, HBV) infection that seriously endangers human health. Despite the successful use of preventive vaccines for many years, hepatitis B remains one of the major public health problems worldwide. According to statistics, more than 350 million people in the world are chronically infected with HBV, and the number of HBV infected people in my country is 93 million. About 20% to 40% of HBV-infected patients will eventually develop serious liver diseases, such as liver cirrhosis and liver cancer. HBV infection has become a major problem endangering public health. At present, the commonly used antiviral drugs for hepatitis B mainly fall into...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/113C12N15/88A61K48/00A61K47/69A61K47/59A61K9/127A61P31/20A61P1/16
CPCA61K48/0041A61K48/0058C12N15/1131C12N15/88C12N2310/10C12N2800/80
Inventor 徐宇虹房文慧彭金良刘君
Owner SHANGHAI JIAO TONG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com